Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hydroxychloroquine (HCQ) had shown efficacy in treating Immunoglobulin A nephropathy (IgAN). There are currently no clinical studies evaluating whether the efficacy and safety of HCQ differ in IgAN with concurrent nasopharyngeal or intestinal mucosal and non-mucosal infections at the time of diagnosis.
This prospective multicenter cohort study enrolled patients aged >18 years with biopsy-proven IgAN who had received optimized renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for at least 1 month, 24-hour urinary protein creatinine ratio (UPCR) of 0.75-3.5 g/g and estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73m². At the time of IgAN diagnosis, patients were divided into the mucosal infection (MI) group and the non-mucosal infection (NMI) group based on whether they had mucosal infections, both groups of patients were treated with HCQ.
The study enrolled a total of 369 participants, consisting of 192 MI patients and 177 NMI patients (Figure 1). The mean age of the study participants was 37.58 years, with an average eGFR of 85.27 mL/min/1.73 m² and a baseline 24-hour UPCR of 1.92 g/g (Table 1). After 12 months, the MI group showed a significant reduction in 24-hour UPCR, decreasing from 1.90 ± 0.76 g/g to 0.77 ± 0.31 g/g, with a mean reduction of 58.6%. In contrast, the NMI group had a more modest decline, from 1.94 ± 0.67 g/g to 1.08 ± 0.44 g/g, averaging a 43.8% reduction (Figure 2 A and 2 B). Complete remission rate was achieved in 58.3% (n = 112) of the MI group and 47.5% (n = 84) of the NMI group (HR: 1.56, 95% CI: 1.15 - 2.13, P = 0.004, Figure 2 C). The overall remission rate was 66.1% (n = 127) in the MI group and 57.6% (n = 102) in the NMI group (HR: 1.65, 95% CI: 1.23 - 2.21, P < 0.001, Figure 2 D) . Renal function remained stable (Figure 3A and 3B), the reduction in urinary RBC was more pronounced in the MI group, with a median decrease of 45.1% compared to 35.7% in the NMI group (Figure 3 C), no severe adverse events were reported (Table 2).
HCQ combined with optimized RAASi safely and effectively reduced proteinuria in IgAN, with particularly superior efficacy observed in patients with concurrent nasopharyngeal or intestinal MI.
